The FDA had previously said Lilly’s drugs were out of shortage and that making copies must cease in October. Compounders sued, causing the FDA to pause enforcement while it reevaluated its decision.
The state will eventually recoup much of that investment when LEAP land is sold to tenants, officials from the Indiana Economic Development Corp. said.
The gift is the largest grant that Indiana University has ever received in support of research and development. IU President Pamela Whitten said the funding will help “change the very landscape of our capital city and state.”
The state’s job-creation agency is seeking $27 million to purchase about 307 acres and pay for deposits and option payments for additional land west of Interstate 65. Another $33 million is being sought for infrastructure work.
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and Drug Administration granted a breakthrough device designation to the product.
Under pressure to keep up with soaring demand for drug treatments for obesity, diabetes and other diseases, Eli Lilly and Co. is planning its single largest U.S. manufacturing investment outside of Indiana.
David Adams, a former state workforce development commissioner, will be Indiana’s next secretary of commerce in Indiana Gov.-elect Mike Braun’s administration, while current Secretary of Education Katie Jenner will continue to lead the state’s education system.
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its next big steps: regulatory approval and commercial launch.
While the proposed rule would give millions of people access to weekly injectables like Eli Lilly and Co.’s Zepbound that have helped people shed pounds, it would cost taxpayers as much as $35 billion over the next decade.
The Lebanon City Council on Monday night approved the creation of a tax-increment financing district and performance-based incentives to try to secure a deal with the parent of Facebook and Instagram.
